New Drugs, Deals Put Pharma Under Insider Trading Microscope

Law360, New York (November 20, 2012, 10:23 PM EST) -- Insider trading indictments this week involving Sanofi-Aventis, Stryker Corp. and Wyeth LLC underscore the need for tighter control of information in the pharmaceutical industry, where companies can live or die on a single clinical trial or drug approval and where a new wave of consolidation is driving high-stakes mergers.

On Tuesday, a former hedge fund portfolio manager was accused in New York federal court of earning a record $276 million by trading on unpublished results from a new Alzheimer's drug trial, gleaned from a doctor involved...
To view the full article, register now.